Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

Published:2014-04-20 Issue:12 Volume:39 Page:1349-1362
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Stidham R. W.¹,Lee T. C. H.²,Higgins P. D. R.¹,Deshpande A. R.³,Sussman D. A.³,Singal A. G.⁴,Elmunzer B. J.¹,Saini S. D.¹⁵,Vijan S.²⁵,Waljee A. K.¹⁵

Affiliation:

1. Division of Gastroenterology and Hepatology; Department of Internal Medicine; University of Michigan Health System; Ann Arbor MI USA

2. Division of General Medicine; Department of Internal Medicine; University of Michigan; Ann Arbor MI USA

3. Division of Gastroenterology; Department of Internal Medicine; University of Miami Miller School of Medicine; Miami FL USA

4. Division of Digestive and Liver Diseases; Department of Internal Medicine; UT Southwestern Medical Center; Dallas TX USA

5. Center for Clinical Management Research; Ann Arbor Veterans Affairs Healthcare System; Ann Arbor MI USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.12749/fullpdf

Reference46 articles.

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group;Targan;N Engl J Med,1997

2. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

3. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease;Schreiber;Gastroenterology,2005

4. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

5. Certolizumab pegol for the treatment of Crohn's disease;Sandborn;N Engl J Med,2007

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of early remission after infliximab in Crohn’s disease using baseline microbiome and metabolomics;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. Low muscle mass is associated with efficacy of biologics in Crohn's disease;Clinical Nutrition;2024-10

3. Certolizumab Pegol in Crohn's Disease Management: A Multicentric Brazilian Observational Study;Journal of Coloproctology;2024-09

4. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

5. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023;Intestinal Research;2024-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3